Template:Testosterone levels with cyproterone acetate
Appearance
Testosterone levels with cyproterone acetate
-
Testosterone levels with 300 mg/week cyproterone acetate or 100 mg/month estradiol undecylate both by intramuscular injection in men.[2] Solid lines are average and dashed lines highest and lowest levels. Levels of testosterone decreased by 75% with cyproterone acetate and by 91% with estradiol undecylate.[2]
-
Testosterone levels with different doses of cyproterone acetate (CPA), segesterone acetate (SGA), norethisterone acetate (NETA), and levonorgestrel (LNG) alone then in combination with transdermal testosterone followed by discontinuation and recovery in healthy young men.[4] Levels decreased by about 65% with cyproterone acetate alone.[4] There were no differences in gonadotropin levels with 10 versus 20 mg/day cyproterone acetate and testosterone levels for the two groups were combined.[4]
-
Testosterone levels with 100 to 300 mg/day oral cyproterone acetate and low-dose oral estrogen in men.[11] The estrogen used was 0.1 mg/day diethylstilbestrol (DES),[11] which has been described as an "extremely low" dosage.[12] Levels of testosterone were decreased by about 95% with the combination and by about 61% with cyproterone acetate only.[11]
-
Testosterone levels with estradiol (E2) alone or in combination with an antiandrogen (AA) in the form of spironolactone (SPL) or cyproterone acetate (CPA) in transfeminine people.[14] Estradiol was used in the form of oral estradiol valerate (EV) in almost all cases.[14] The dashed horizontal line is the upper limit of the female/castrate range (~50 ng/dL).
Template documentation
Usage
This template can be used to easily insert a number of graphs with detailed captions and pre-provided references into an article.
This template takes no parameters.
See also
References
- ^ a b Fourcade RO, McLeod D (2015). "Tolerability of Antiandrogens in the Treatment of Prostate Cancer". UroOncology. 4 (1): 5–13. doi:10.1080/1561095042000191655. ISSN 1561-0950.
- ^ a b Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (June 1980). "Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial". British Journal of Urology. 52 (3): 208–215. doi:10.1111/j.1464-410x.1980.tb02961.x. PMID 7000222.
- ^ a b Meriggiola MC, Bremner WJ, Costantino A, Bertaccini A, Morselli-Labate AM, Huebler D, et al. (May 2002). "Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men". The Journal of Clinical Endocrinology and Metabolism. 87 (5): 2107–2113. doi:10.1210/jcem.87.5.8514. hdl:1773/4465. PMID 11994349. S2CID 3251197.
- ^ a b c Zitzmann M, Rohayem J, Raidt J, Kliesch S, Kumar N, Sitruk-Ware R, Nieschlag E (May 2017). "Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial". Andrology. 5 (3): 516–526. doi:10.1111/andr.12328. PMID 28189123. S2CID 41502711.
- ^ a b Wang C, Yeung KK (March 1980). "Use of low-dosage oral cyproterone acetate as a male contraceptive". Contraception. 21 (3): 245–272. doi:10.1016/0010-7824(80)90005-0. PMID 6771091.
- ^ a b Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J (April 1980). "Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men". Contraception. 21 (4): 393–413. doi:10.1016/s0010-7824(80)80017-5. PMID 6771095.
- ^ a b Moltz L, Römmler A, Schwartz U, Post K, Hammerstein J (1978). "252. Cyproterone acetate (CPA)-a potential male contraceptive: further studies on the interactions with endocrine parameters". Journal of Steroid Biochemistry. 9 (9): 865. doi:10.1016/0022-4731(78)90952-4. ISSN 0022-4731.
- ^ a b Moltz L, Römmler A, Schwartz U, Hammerstein J (1978). "Effects of Cyproterone Acetate (CPA) on Pituitary Gonadotrophin Release and on Androgen Secretion Before and After LH-RH Double Stimulation Tests in Men". International Journal of Andrology. 1 (s2b): 713–719. doi:10.1111/j.1365-2605.1978.tb00518.x. ISSN 0105-6263.
- ^ a b Koch UJ, Lorenz F, Danehl K, Ericsson R, Hasan SH, Keyserlingk DV, et al. (August 1976). "Continuous oral low-dosage cyproterone acetate for fertility regulation in the male? A trend analysis in 15 volunteers". Contraception. 14 (2): 117–135. doi:10.1016/0010-7824(76)90081-0. PMID 949890.
- ^ a b Koch UJ, Lorenz F, Danehl K, Hammerstein J (November 1975). "Über die Verwendbarkeit von Cyproteronacetat zur Fertilitätshemmung beim Mann. Morphologische Veränderungen und Einflüsse auf die Spermienmotilität" [Use of cyproterone acetate for fertility inhibition in the male. Morphologic changes and influences on sperm motility]. Archiv Fur Gynakologie (in German). 219 (1–4): 581–582. doi:10.1007/BF00669258. PMID 1243497. S2CID 21841034.
- ^ a b c Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM (December 1988). "The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma". The Journal of Urology. 140 (6): 1460–1465. doi:10.1016/S0022-5347(17)42073-8. PMID 2973529.
- ^ Schröder FH, Radlmaier A (2009). "Steroidal Antiandrogens". In V. Craig Jordan, Barrington J. A. Furr (eds.). Hormone Therapy in Breast and Prostate Cancer. Humana Press. pp. 325–346. doi:10.1007/978-1-59259-152-7_15. ISBN 978-1-60761-471-5.
- ^ a b Gava G, Cerpolini S, Martelli V, Battista G, Seracchioli R, Meriggiola MC (August 2016). "Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness". Clinical Endocrinology. 85 (2): 239–246. doi:10.1111/cen.13050. PMID 26932202. S2CID 30150360.
- ^ a b Angus L, Leemaqz S, Ooi O, Cundill P, Silberstein N, Locke P, et al. (July 2019). "Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy". Endocrine Connections. 8 (7): 935–940. doi:10.1530/EC-19-0272. PMC 6612061. PMID 31234145.